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Background
There is a great deal of variability in the survival of
patients diagnosed with renal cell carcinoma (RCC) that
is not explained by the classical clinic-pathological mea-
sures of aggressiveness such as tumor stage or tumor
grade. There is an urgent need to identify more accurate
molecular and/or metabolic signatures that are predic-
tive of tumor behavior. Such signatures should improve
our ability to quantify the risk of progression in indivi-
dual RCC cases and make accurate prognostic predic-
tions. These measures may also allow oncologists to
personalize therapy and identify new targets for drug
development. To date, most biomarker research in RCC
has centered on von Hippel-Lindau mutations, VEGF,
and hypoxia-inducible factors.
Methods
We have previously shown that increases in the enzyme
arginase 2 (ARG2) in RCC tumors is associated with
increased polyamine synthesis by tumor cells to sustain
their rapid proliferation. In contrast, high levels of nitric
oxide synthase (NOS2) and nitric oxide (NO) are asso-
ciated with slower tumor growth. We sought to validate
these findings and determine whether plasma ARG2 is a
putative biomarker of RCC activity. analyzed samples
obtained from the LCRC Bio-repository.
Results
We found that ARG2 is expressed at high levels in high-
grade clear RCC compared to low-grade RCC. Conco-
mitantly, we observed that NOS2 expression was weakly
expressed in high ARG2-expressing tumors. Expression
of the two enzymes were confirmed by enzymatic assays,
Western blots and HPLC. High ARG2 and low NOS2
expression strongly correlate (r=0.913) with disease
progression and short disease-free survival, in contrast
to low ARG2 and high NOS2. Importantly, when we
tested the levels of ARG2 in the blood of 32 (12 African
American and 20 Caucasians) RCC patients, we found
significantly higher expression of ARG2 (p=0.02) in
African Americans compared to Caucasians and normal
controls.
Conclusions
The results of this study indicate that: 1) ARG2 and
NOS2 expression in RCC can be sensitive indicators of
tumor activity; 2) Plasma ARG2 may be a useful predic-
tive biomarker and may be linked to health disparities;
3) ARG2 may be a promising therapeutic target in RCC,
particularly in African-American patients.
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